[{"id":"68aa0036-1540-4538-858b-bf876fa2e9ec","acronym":"RACING","url":"https://clinicaltrials.gov/study/NCT03745430","created_at":"2021-01-18T18:20:40.965Z","updated_at":"2025-02-25T14:27:50.093Z","phase":"Phase 1/2","brief_title":"RAmucirumab Combined wIth Standard Nab-paclitaxel and Gemcitabine as First-line Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT03745430 - RACING","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9","pipe":" | ","alterations":" EGFR mutation • PTEN mutation","tags":["PTEN • FLT1 • SPARC • THBS1 • EREG • MMP2 • VEGFB • MMP9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 01/29/2019","start_date":" 01/29/2019","primary_txt":" Primary completion: 06/17/2022","primary_completion_date":" 06/17/2022","study_txt":" Completion: 04/23/2023","study_completion_date":" 04/23/2023","last_update_posted":"2023-05-24"},{"id":"66bc3f88-573e-483d-a074-c5b181266d2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01297244","created_at":"2021-01-18T05:16:20.218Z","updated_at":"2024-07-02T16:36:39.586Z","phase":"Phase 2","brief_title":"A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma","source_id_and_acronym":"NCT01297244","lead_sponsor":"AVEO Pharmaceuticals, Inc.","biomarkers":" HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68","pipe":"","alterations":" ","tags":["HGF • IL2 • VEGFD • CA9 • VEGFB • VEGFC • CD68"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fotivda (tivozanib)"],"overall_status":"Completed","enrollment":" Enrollment 105","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 10/01/2012","primary_completion_date":" 10/01/2012","study_txt":" Completion: 10/01/2012","study_completion_date":" 10/01/2012","last_update_posted":"2020-10-27"},{"id":"5881532e-c856-4fdf-b007-62afa39b90eb","acronym":"PERMAD","url":"https://clinicaltrials.gov/study/NCT02331927","created_at":"2021-01-18T11:04:13.685Z","updated_at":"2024-07-02T16:36:55.376Z","phase":"Phase 2","brief_title":"PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT02331927 - PERMAD","lead_sponsor":"University of Ulm","biomarkers":" VEGFB","pipe":"","alterations":" ","tags":["VEGFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • irinotecan • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Unknown status","enrollment":" Enrollment 150","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2019-09-20"},{"id":"5d6a13b7-0d2f-4bad-b517-6aad5b7c8e21","acronym":"","url":"https://clinicaltrials.gov/study/NCT01282463","created_at":"2021-01-18T05:12:09.851Z","updated_at":"2024-07-02T16:36:55.890Z","phase":"Phase 2","brief_title":"Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma","source_id_and_acronym":"NCT01282463","lead_sponsor":"Eli Lilly and Company","biomarkers":" KDR • FLT1 • VEGFB","pipe":"","alterations":" ","tags":["KDR • FLT1 • VEGFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Cyramza (ramucirumab) • icrucumab (IMC-18F1)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2019-09-09"},{"id":"b90c7697-6311-4262-9536-bc47534419d3","acronym":"AMALTHEA","url":"https://clinicaltrials.gov/study/NCT02129257","created_at":"2021-01-18T09:52:23.572Z","updated_at":"2024-07-02T16:37:16.932Z","phase":"Phase 2","brief_title":"Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT02129257 - AMALTHEA","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1","pipe":"","alterations":" ","tags":["KDR • HGF • HIF1A • FLT1 • VEGFB • VEGFC • FGF • NRP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • Zaltrap (ziv-aflibercept IV)"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 05/26/2014","start_date":" 05/26/2014","primary_txt":" Primary completion: 01/01/2017","primary_completion_date":" 01/01/2017","study_txt":" Completion: 09/25/2017","study_completion_date":" 09/25/2017","last_update_posted":"2017-10-24"},{"id":"99cff952-63e7-41ad-9422-fc6faa92464b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00897754","created_at":"2021-01-18T03:26:40.172Z","updated_at":"2024-07-02T16:37:21.957Z","phase":"","brief_title":"Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab","source_id_and_acronym":"NCT00897754","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" VEGFA • VEGFB","pipe":"","alterations":" ","tags":["VEGFA • VEGFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 07/24/2007","start_date":" 07/24/2007","primary_txt":" Primary completion: 02/01/2009","primary_completion_date":" 02/01/2009","study_txt":" Completion: 02/01/2009","study_completion_date":" 02/01/2009","last_update_posted":"2017-05-19"}]